0.08 | 0.51%
REPROS THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2013 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line.
During the same period, stockholders' equity ("net worth") has increased by 24.36% from the same quarter last year.
| Income Statement | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Net Sales ($mil) | 0.0 | 0.0 |
| EBITDA ($mil) | 0.0 | -2.41 |
| EBIT ($mil) | -7.37 | -2.44 |
| Net Income ($mil) | -7.37 | -2.44 |
| Balance Sheet | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 17.15 | 12.11 |
| Total Assets ($mil) | 19.92 | 14.01 |
| Total Debt ($mil) | 0.0 | 0.0 |
| Equity ($mil) | 16.29 | 13.1 |
| Profitability | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Gross Profit Margin | -737400.0 | 0.0 |
| EBITDA Margin | 0.0 | 0.0 |
| Operating Margin | -737400.0 | 0.0 |
| Sales Turnover | 0.0 | 0.0 |
| Return on Assets | -116.0 | -91.48 |
| Return on Equity | -141.82 | -97.83 |
| Debt | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Current Ratio | 4.83 | 13.65 |
| Debt/Capital | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 |
| Interest Coverage | 0.0 | 0.0 |
| Share Data | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Shares outstanding (mil) | 18.64 | 14.82 |
| Div / share | 0.0 | 0.0 |
| EPS | -0.41 | -0.17 |
| Book value / share | 0.87 | 0.88 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 770446.0 | 552820.0 |
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPRX NM | Peers 24.42 | RPRX NA | Peers 18.01 | |||||||||||||||||||||
|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. RPRX's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures. Ratio not available. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| RPRX NM | Peers 15.97 | RPRX NA | Peers 0.63 | |||||||||||||||||||||
|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. RPRX's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| RPRX NA | Peers 6.58 | RPRX -37.62 | Peers -7.87 | |||||||||||||||||||||
|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. Ratio not available. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, RPRX is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| RPRX 0.00 | Peers 4.93 | RPRX NA | Peers 13.67 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. RPRX is trading at a significant discount to its industry on this measurement. |
Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share. The growth rate for RPRX is not available. |
|||||||||||||||||||||||
